Pura Vida Investments, LLC Otonomy, Inc. Transaction History

Pura Vida Investments, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$3.48 - $6.47 $5.82 Million - $10.8 Million	-1,671,748 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.16 - $4.36 $1.34 Million - $1.85 Million	424,890 Added 34.08%	1,671,748 $6.77 Million
Q1 2020 May 15, 2020	BUY	$1.58 - $4.06 $168,578 - $433,181	106,695 Added 9.36%	1,246,858 $2.46 Million
Q4 2019 Feb 14, 2020	BUY	$2.13 - $3.83 $312,471 - $561,861	146,700 Added 14.77%	1,140,163 $4.37 Million
Q1 2019 May 14, 2019	BUY	$1.8 - $2.97 $174,736 - $288,315	97,076 Added 10.83%	993,463 $2.61 Million
Q4 2018 Feb 14, 2019	BUY	$1.51 - $2.93 $919,182 - $1.78 Million	608,730 Added 211.62%	896,387 $1.66 Million
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.95 $532,643 - $809,208	204,863 Added 247.44%	287,657 $791,000
Q2 2018 Aug 14, 2018	SELL	$3.7 - $4.75 $257,860 - $331,037	-69,692 Reduced 45.7%	82,794 $319,000
Q1 2018 May 14, 2018	SELL	$4.05 - $6.1 $1.02 Million - $1.54 Million	-252,256 Reduced 62.33%	152,486 $0
Q4 2017 Feb 14, 2018	BUY	$2.8 - $5.55 $1.13 Million - $2.25 Million	404,742	404,742 $0

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Pura Vida Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Pura Vida Investments, LLC with notifications on news.